Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DORIA

Showing results (311-320 of 667) with videos related to

Pageof 67
Sort By:
Vaccines|November 24, 2022
Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1Li Ou, Krishana Gulla, Andrea Biju, et al.
Cell Reports|November 3, 2021
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodiesChristopher A Cottrell, Kartik Manne, Rui Kong, et al.
Science Translational Medicine|November 29, 2019
Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturationJames W Austin, Clarisa M Buckner, Lela Kardava, et al.
Blood|April 12, 2012
Comprehensive analysis of unique cases with extraordinary control over HIV replicationDaniel Mendoza, Sarah A Johnson, Bennett A Peterson, et al.
Nature Structural & Molecular Biology|May 28, 2013
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16Marie Pancera, Syed Shahzad-Ul-Hussan, Nicole A Doria-Rose, et al.
Immunity|November 17, 2019
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of VulnerabilityViktoriya Dubrovskaya, Karen Tran, Gabriel Ozorowski, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 23, 2022
Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2Nan Gao, Yanxin Gai, Lina Meng, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Scientific Reports|October 26, 2022
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half lifeBaoshan Zhang, Deepika Gollapudi, Jason Gorman, et al.
Science Translational Medicine|September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeBoris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
Pageof 67

Showing results (311-320 of 667) with videos related to

Sort By:
Pageof 67
Vaccines|November 24, 2022
Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1Li Ou, Krishana Gulla, Andrea Biju, et al.
Cell Reports|November 3, 2021
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodiesChristopher A Cottrell, Kartik Manne, Rui Kong, et al.
Science Translational Medicine|November 29, 2019
Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturationJames W Austin, Clarisa M Buckner, Lela Kardava, et al.
Blood|April 12, 2012
Comprehensive analysis of unique cases with extraordinary control over HIV replicationDaniel Mendoza, Sarah A Johnson, Bennett A Peterson, et al.
Nature Structural & Molecular Biology|May 28, 2013
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16Marie Pancera, Syed Shahzad-Ul-Hussan, Nicole A Doria-Rose, et al.
Immunity|November 17, 2019
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of VulnerabilityViktoriya Dubrovskaya, Karen Tran, Gabriel Ozorowski, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 23, 2022
Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2Nan Gao, Yanxin Gai, Lina Meng, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Scientific Reports|October 26, 2022
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half lifeBaoshan Zhang, Deepika Gollapudi, Jason Gorman, et al.
Science Translational Medicine|September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeBoris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
Pageof 67